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T cell factor (TCF)-4 and β-catenin are well recognized as key regulators in many developmental processes. TCF-4 
binding with β-catenin can activate the transcriptional activity of downstream target genes (e.g. c-myc and cyclin-
D1). Upregulation of TCF/β-catenin activity can promote carcinogenesis in many tissues. However, its precise role in 
bladder cancer is still unclear. Since typical activating mutations have not been previously reported in the bladder, 
we examined whether TCF-4 mutations occur in human bladder carcinoma cell lines. In the present study, interest-
ingly, TCF-4 gene mutations were found in human bladder carcinoma cell lines as shown by reverse transcription 
polymerase chain reaction and a sequencing method. A TCF-4 microsatellite instability (MSI) phenotype was identi-
fied to be an (A)8 repeat arising from the deletion of an A in the (A)9 coding repeat. Moreover, immunofluorescence 
analysis showed that the frameshift mutant of TCF-4 was exclusively localized in the nucleus of bladder cancer cells. 
Collectively, our data indicate that TCF-4 MSI+ and the expression of spliced forms appear in human bladder cancer 
cells, and suggest a role of the TCF-4-mediated signal pathway in progression of bladder cancer.
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Introduction
Bladder cancer was the eighth most common malig-
nancy in Taiwanese men in 2005 and the 12th leading 
cause of cancer mortality.1 Recent research has iden-
tified that the Wingless/Wnt signaling pathway is 
involved in altering cell fate in several developmental 
processes as well as in morphogenesis, mitogenesis 
and tumorigenesis.2,3 The Wnt signaling pathway 
plays a critical role in development and growth regu-
latory mechanisms.4−6 A critical downstream factor in 
this pathway, β-catenin, is associated with a cyto-
plasmic protein complex comprised glycogen syn-
thase kinase-3β (GSK-3β), adenomatous polyposis 
coli (APC), and axin.7−9 Phosphorylation of β-catenin 
by GSK-3β leads to proteosomal degradation of β-
catenin. Mutations in genes encoding APC or β-catenin 
that enhance the stability of β-catenin have been 
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found in colon carcinoma and melanoma.10,11 Trans-
criptional targets of this signaling pathway include 
cancer-associated genes, such as cyclin D1 and 
c-myc.12,13 Since the APC/β-catenin/T cell factor 
(TCF) pathway plays a vital role in cancer develop-
ment, it is important to understand the role of TCF 
in pathogenesis of tumors.
Recently, genes with mononucleotide runs in their 
coding microsatellite sequences have come to be 
considered to be candidates for mutational inacti-
vation in microsatellite instability (MSI)+ tumors.14−16 
MSI tumors are characterized by defective mismatch 
repair and accumulation of frameshift mutations 
in numerous genes harboring repeats in their cod-
ing sequences. Mutations in coding monotonic runs 
within TGF-bRII, IGFIIR and BAX genes are de-
tected in cancers with MSI.17−20 Mutations targeting 
monotonic runs within two mismatch repair genes, 
hMSH3 and hMSH6, have also been identified in 
MSI+ cancers.21,22 These findings suggest that a re-
petitive sequence in the coding region is a target 
of MSI and is associated with tumorigenesis.
To determine the role of TCF-4 in development 
and in bladder cancer, analysis of TCF-4 variants was 
conducted in human bladder cancer cell lines with 
varying degrees of differentiation for associations 
with clinicopathological markers. Our data showed 
that the TCF-4 MSI mutation and expression of 
spliced forms occur in bladder carcinoma cell lines.
Materials and Methods
Cell culture
TSGH8301, BFTC905, and T24 bladder carcinoma cell 
lines were obtained from the Bioresource Collection 
and Research Center (BCRC, Taiwan). Cell lines 
were maintained in Dulbecco’s modified Eagles me-
dium supplemented with 10% fetal bovine serum 
and 1% penicillin/streptomycin, and incubated in 5% 
CO2 at 37ºC.
Reverse transcription polymerase chain 
reaction (RT-PCR)
Total cellular RNA was isolated from cultured 
TSGH8301, BFTC905, and T24 bladder carcinoma cell 
lines using TRIzol reagent (Life Technologies, Inc., 
Carlsbad, CA, USA). Reverse transcribed cDNA was 
performed using Superscript II RT RNase H-reverse 
transcriptase and random primers (Life Technologies, 
Inc.). Quantity and quality of mRNA from all samples 
were verified by RT-PCR amplification of the b-actin 
cDNA. Amplification of TCF-4 transcripts was per-
formed using the Perkin-Elmer GeneAmp PCR sys-
tem 9600 (Perkin-Elmer, Norwalk, CT, USA) and 
oligonucleotide primers (TCF-4F: 5-ATGCCGCAG
CTGAACGGCGGT-3; TCF-4R: 5-CTATTCTAAAGACTT
GGTGAC-3). Thermal conditions of the system 
were as follows: 94ºC for 2 minutes; 30 cycles at 
94ºC for 15 seconds, 55ºC for 30 seconds, 72ºC for 
2 minutes; one cycle at 72ºC for 10 minutes. The 
resulting PCR products (20 μL) were resolved in a 
2% agarose gel and visualized under UV light after 
ethidium bromide staining.
Cloning and sequences
PCR products were purified by using a QIAquick PCR 
Purification Kit (Qiagen, Venlo, Netherlands) and 
cloned into the pGEM-T easy vector (Promega Co., 
Fitchburg, MI, USA). The nucleotide sequence was 
determined using an ABI PRISM 310 DNA Sequencer 
(Perkin-Elmer).
Plasmid construction
The TCF-4 MSI+ expression clone was constructed by 
PCR with appropriate primers providing an initiation 
codon and a stop codon and was cloned into the 
pCDNA3-HA (Invitrogen, Carlsbad, CA, USA) and 
pEGFP-C1 (Clontech Laboratories, Inc., San Francisco, 
CA, USA) vectors. The constructs were confirmed 
by restriction endonuclease digestion and sequenc-
ing. Detailed procedures for plasmid construction 
are available on request.
Transfection and fluorescent microscopy
Subcellular localization of MSI+ TCF-4 was exam-
ined by transfection and fluorescent microscopy. 
Transfection was performed in duplicate on cell 
plates at a density of 3 × 105 cells/well in six-well 
plates, using 1 mL of Opti-MEM reduced serum me-
dium (Life Technologies, Inc.), 5 μL of lipofectamine 
2000 reagent, and 1 μg of each plasmid (pEGFP-C1-
TCF-4). After 24 hours, images were obtained by fluo-
rescent microscopy (Olympus Co., Tokyo, Japan).
Results
Bladder carcinoma cell lines express 
TCF-4 splicing forms
TCF families are well known as key activators/re-
pressors in many developmental processes. TCF-4 
binding with β-catenin can activate transcriptional 
activity and activate downstream target genes (e.g. 
c-myc and cyclin-D1). Mutations in b-catenin con-
tribute to elevation of β-catenin/TCF transactivation 
in colorectal cell lines.23 Since the APC/catenin/
TCF pathway plays an important role in colorectal 
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cancer development, mutational analysis of these 
genes is critical for determining their functions. 
Therefore, mutational analysis of the TCF-4 gene 
in bladder carcinoma cell lines was performed by 
RT-PCR (Figure 1). Figure 1 shows PCR amplifica-
tion of TCF-4 cDNA fragments with primers de-
signed from the positions of 1291 to 1791. The 
amplified TCF-4 cDNA fragments were 300−500 bp. 
Four new TCF-4 splicing forms were designated as 
TCF-4E*, TCF-4E*(d17), TCF-4E(d17), and TCF-
4B(I17) (Figure 2). They differ in the Groucho-binding 
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Figure 1 Mutational analysis of T cell factor-4 cDNA in 
bladder cancer cells by reverse transcription polymer-
ase chain reaction. Total cellular RNA was isolated from 
cultured TSGH8301, BFTC905, and T24 bladder carcinoma 
cell lines.
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Figure 2 Four new T cell factor (TCF)-4 splicing forms. 
These new splicing forms were designated as TCF-4E*, 
TCF-4E*(d17), TCF-4E(d17), and TCF-4B(I17). Splicing 
sites and the number of amino acids are indicated. The 
amino acids sequence DLSAPKKCRARFGLDQQNNWCGPR 
is depicted by pink box and the amino acids sequence 
DSNTPKKCRALFGLDRQTLWCKPR is depicted by yellow box.
domain and the region immediately downstream 
of the High-Mobility-Group box of TCF-4.
TCF-4 MSI phenotype in bladder carcinoma 
cell lines
Human TCF-4 is a member of the TCF-4/lymphoid 
enhancing factor family, and is an important tran-
scription factor. Deregulation of TCF/β-catenin ac-
tivity can promote carcinogenesis in many tissues. 
Alteration of the components in the Wnt signaling 
pathway in colorectal cancer with MSI has been dem-
onstrated. However, one group could not confirm 
an (A)10 or more sequence in colorectal cancer by 
sequence analysis.24 The TCF-4 MSI+ phenotype 
has been found in leukemia cell lines, but not in 
colon cancer cell lines.25 Moreover, these cell lines 
exhibit deletion and insertion of 1−2 As in an (A)9 
repeat resulting in (A)7, (A)8, (A)10 and (A)11 re-
peats. We examined whether TCF-4 mutations occur 
in human bladder carcinoma cell lines with different 
degrees of differentiation. We found that TCF-4 
gene mutations occurred in bladder carcinoma cell 
lines as shown by RT-PCR and sequencing. We de-
scribe, for the first time, a TCF-4 MSI+ phenotype in 
bladder cancer cell lines with deletion of an A in 
the (A)9 coding repeat resulting in an (A)8 repeat. 
Figure 3 shows that the TCF-4 MSI+ phenotype had 
an (A)8 repeat resulting from deletion of an A in the 
[A] 9 coding repeat in bladder cancer cells. β-catenin 
interacts with transcription factors of the TCF 
family and subsequently activates genes that are 
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Figure 3 Nucleotides sequence analysis of T cell factor 
(TCF)-4. (A) Wildtype TCF-4 sequence, (A)9 in normal blad-
der cells. (B) Mutated TCF-4 sequence (A)8 in TSGH8301 
bladder cancer cells.
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responsive to TCF family members.26 Thus defects 
in the β-catenin/TCF pathway may play a role in 
MSI+ TCF4 in bladder cancer. To determine the role 
played by MSI+ TCF4 in bladder cancer, we need to 
design a transfection assay with pTOPFLASH or pFOP-
FLASH, which directly assays β-catenin-TCF activity.
Localization of TCF-4 MSI+ frameshift 
gene products
We found that mutations of the TCF-4 (A)9 repeat 
resulted in an (A)8 repeat of TCF-4 in bladder car-
cinoma cell lines. We considered whether mutations 
in the (A)9 repeat of TCF-4 influenced the expression 
and localization of TCF-4 in cells leading to changes 
in the interaction between β-catenin and TCF-4 
complexes. To resolve this issue, transient trans-
fection and fluorescent microscopy were performed. 
We found that GFP-tagged TCF-4 (A)8 was localized 
in the nuclei of bladder cancer cells (Figure 4). 
Control green fluorescence was observed with an 
empty vector. Based on these results, we believe 
that the localization of TCF-4 MSI+ remains un-
changed. The cellular localization of TCF-4 MSI+ may 
perturb the protein−protein interaction between 
TCF-4 and β-catenin. Further experiments are re-
quired to consolidate this putative role of MSI+ TCF-4 
with β-catenin in cancer progression.
Discussion
The multistep development of malignant tumors 
with increasing accumulation of genetic alterations 
from preneoplastic lesions to invasive carcinoma is 
an accepted model of carcinogenesis.27 Molecular re-
search on bladder cancer is beneficial for its preven-
tion, diagnostics and therapy. Urothelial carcinoma 
of the bladder and upper urinary tract is a useful 
mode to study tumor development and progres-
sion.28,29 Either genome-wide screens or candidate 
gene analysis can be conducted for elucidating 
molecular mechanisms that elicit bladder cancer. 
Human TCF-4 is a member of the TCF-4 or lym-
phoid enhancing factor family and is as an important 
transcription factor.5 Recent studies have found 
that TCF-4 regulates a certain set of genes related 
to growth and differentiation of epithelial cells.30 
Studies on papillary bladder cancers for progression-
related genetic alterations have shown that muta-
tions in the Wnt pathway genes including APC and 
beta-catenin do not play an important role in uro-
thelial carcinogenesis.31 However, mutations of TCF-4 
have been found in two of four MSI upper urinary 
tract urothelial cell carcinomas.29 Alternatively, tu-
mors of the ureter and renal pelvis develop through 
a different genetic pathway in 30% of cases.32
Microsatellite repeats are widely distributed 
throughout the genome. Frameshift mutations in 
genes containing mononucleotide repeats are often 
observed in cancers exhibiting a high frequency of 
MSI.14−16 TGFbRII was reported as the first target gene 
for instability in human colorectal MSI-H tumors.17 
The loss of mismatch repair proteins (hMSH2, hMLH1 
or hMSH6) leads to a mutator phenotype with ac-
cumulation of genetic alterations in multiple repe-
ti tive sequences.21,22 The transcription factor TCF-4 
is one of the TCF-family proteins, which forms a 
transcription complex with β-catenin and plays an 
im portant role in maintaining normal epithelial 
growth and development of colorectal tumors.33 Our 
data further suggest a fascinating possibility of the 
association of TCF-4 mutations with bladder cancer. 
The TCF4 MSI+ phenotype has a deletion of the 1A 
nucleotide in (A)9 repeats, resulting in (A)8 repeats. 
Transfection with frameshift mutations showed that 
A B
Figure 4 Immunolocalization of T cell factor (TCF)-4 microsatellite instability (MSI) in the human bladder cancer 
cell line TSGH8301 by immunofluorescence microscopy. (A) Transfection with the green fluorescent protein−tagged 
TCF-4 MSI + frameshift product (pEGFP-C1-TCF4A8). (B) Transfection with an empty vector (pEGFP-C1) in the human 
bladder cancer cell line TSGH8301.
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the frameshift mutant is localized in nuclei. These 
data suggest that TCF mutations are involved in the 
development of bladder tumor. Currently, bladder 
tumor tissues and paired normal tissues from the 
same patients are being collected in the Department 
of Surgery and Division of Urology, Zouying Armed 
Forces General Hospital, Kaohsiung, Taiwan. The 
MSI status and mutations of TCF-4 in bladder tumor 
tissues will be evaluated in future studies.
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